1. Home
  2. AMAL vs GHRS Comparison

AMAL vs GHRS Comparison

Compare AMAL & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amalgamated Financial Corp. (DE)

AMAL

Amalgamated Financial Corp. (DE)

HOLD

Current Price

$39.83

Market Cap

1.2B

Sector

Finance

ML Signal

HOLD

Logo GH Research PLC

GHRS

GH Research PLC

HOLD

Current Price

$21.65

Market Cap

947.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMAL
GHRS
Founded
1923
2018
Country
United States
Ireland
Employees
450
N/A
Industry
Commercial Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
947.2M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
AMAL
GHRS
Price
$39.83
$21.65
Analyst Decision
Hold
Strong Buy
Analyst Count
2
8
Target Price
$36.00
$41.38
AVG Volume (30 Days)
114.5K
255.2K
Earning Date
04-23-2026
05-01-2026
Dividend Yield
1.68%
N/A
EPS Growth
N/A
N/A
EPS
0.84
N/A
Revenue
N/A
N/A
Revenue This Year
$21.18
N/A
Revenue Next Year
$6.55
N/A
P/E Ratio
$48.10
N/A
Revenue Growth
N/A
N/A
52 Week Low
$25.13
$10.67
52 Week High
$44.01
$24.66

Technical Indicators

Market Signals
Indicator
AMAL
GHRS
Relative Strength Index (RSI) 42.52 60.68
Support Level $36.50 $12.41
Resistance Level $40.89 $22.88
Average True Range (ATR) 1.04 1.33
MACD -0.26 -0.07
Stochastic Oscillator 7.86 67.96

Price Performance

Historical Comparison
AMAL
GHRS

About AMAL Amalgamated Financial Corp. (DE)

Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management, and trust and custody services.

About GHRS GH Research PLC

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

Share on Social Networks: